Diagnosis and management of neurotrophic keratitis

Clinical Ophthalmology

Volumn 8, Issue , 2014, Pages 571-579

  Sacchetti, Marta ^a   Lambiase, Alessandro ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cornea innervation; Cornea sensitivity; Neurotrophic keratitis; Persistent epithelial defect

Indexed keywords

ARTIFICIAL TEAR; BOTULINUM TOXIN A; CACICOL 20; EPIDERMAL GROWTH FACTOR; EYE DROPS; FIBRIN GLUE; NERVE GROWTH FACTOR; NEUROPEPTIDE; PHENYLALANYLGLYCYLLEUCYLMETHIONINE AMIDE; RECOMBINANT NERVE GROWTH FACTOR; SOMATOMEDIN C; STEROID; SUBSTANCE P; THYMOSIN BETA4; UNCLASSIFIED DRUG;

AMNIOTIC MEMBRANE TRANSPLANTATION; CLINICAL FEATURE; CONFOCAL MICROSCOPY; CONJUNCTIVAL FLAP; CONTACT LENS; CORNEA SENSIBILITY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE SEVERITY; EYE EXAMINATION; EYE SURGERY; HUMAN; IMPRESSION CYTOLOGY; INCIDENCE; KERATITIS; MEDICAL HISTORY; NEUROTROPHIC KERATITIS; PREVALENCE; PROGNOSIS; REVIEW; SCHIRMER TEST; TARSORRHAPHY; THROMBOCYTE RICH PLASMA; TISSUE FLAP; TRANSPLANTATION;

EID: 84896451115     PISSN: 11775467     EISSN: 11775483     Source Type: Book Series    
DOI: 10.2147/OPTH.S45921     Document Type: Review

References (63)

1. Bonini S, Rama P, Olzi D, Lambiase A. Neurotrophic keratitis. Eye (Lond). 2003;17:989-995.
2. Groos EB Jr. Neurotrophic keratitis. In: Krachmer JH, Mannis MJ, Holland EJ, editors. Cornea: Clinical Diagnosis and Management. St Louis, MO, USA: Mosby; 1997.
3. Magendie F. De l'influence de la cinquieme paire de nerfs sur la nutrition et les fonctions de l'oeil. [The influence of the fifth pair of nerves on nutrition and function of the eye]. J Physiol Exp Pathol. 1824;4:176-182. French.
4. Müller LJ, Marfurt CF, Kruse F, Tervo TM. Corneal nerves: structure, contents and function. Exp Eye Res. 2003;76:521-542.
5. Labetoulle M, Auquier P, Conrad H, et al. Incidence of herpes simplex virus keratitis in France. Ophthalmology. 2005;112:888-895.
6. Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007;44 Suppl 1: S1-S26.
7. Bhatti MT, Patel R. Neuro-ophthalmic considerations in trigeminal neuralgia and its surgical treatment. Curr Opin Ophthalmol. 2005;16: 334-340.
8. Mackie IA. Neuroparalytic keratitis. In: Fraunfelder F, Roy FH, Meyer SM, editors. Current Ocular Therapy. Philadelphia, PA, USA: WB Saunders; 1995.
9. Faulkner WJ, Varley GA. Corneal diagnostic technique. In: Krachmer JH, Mannis MJ, Holland EJ, editors. Cornea: Fundamentals of Corneal and External Disease. St Louis, MO, USA: Mosby; 1997.
10. Norn MS. Measurement of sensitivity. In: Norn MS, editor. External Eye Diseases. Methods of Examination. Copenhagen, Denmark: Munksgaard International Publisher Ltd; 1974.
11. 2 esthesiometer. Invest Ophthalmol Vis Sci. 1999;40:513-519.
12. Mandahl A. Hypertonic saline test for ophthalmic nerve impairment. Acta Ophthalmol (Copenh). 1993;71:556-559.
13. Heigle TJ, Pflugfelder SC. Aqueous tear production in patients with neurotrophic keratitis. Cornea. 1996;15:135-138.
14. Patel DV, McGhee CN. In vivo confocal microscopy of human corneal nerves in health, in ocular and systemic disease, and following corneal surgery: a review. Br J Ophthalmol. 2009;93:853-860.
15. Hamrah P, Cruzat A, Dastjerdi MH, et al. Unilateral herpes zoster ophthalmicus results in bilateral corneal nerve alteration: an in vivo confocal microscopy study. Ophthalmology. 2013;120:40-47.
16. Hamrah P, Cruzat A, Dastjerdi MH, et al. Corneal sensation and subbasal nerve alterations in patients with herpes simplex keratitis: an in vivo confocal microscopy study. Ophthalmology. 2010;117:1930-1936.
17. Linna TU, Vesaluoma MH, Pérez-Santonja JJ, Petroll WM, Alió JL, Tervo TM. Effect of myopic LASIK on corneal sensitivity and morphology of subbasal nerves. Invest Ophthalmol Vis Sci. 2000;41: 393-397.
18. Rosenberg ME, Tervo TM, Immonen IJ, et al. Corneal structure and sensitivity in type 1 diabetes mellitus. Invest Ophthalmol Vis Sci. 2000;41:2915-2921.
19. Cruzat A, Pavan-Langston D, Hamrah P. In vivo confocal microscopy of corneal nerves: analysis and clinical correlation. Semin Ophthalmol. 2010;25:171-177.
20. Lambiase A, Sacchetti M, Mastropasqua A, Bonini S. Corneal changes in neurosurgically induced neurotrophic keratitis. JAMA Ophthalmol. 2013;131:1547-1553.
21. Scarpa F, Zheng X, Ohashi Y, Ruggeri A. Automatic evaluation of corneal nerve tortuosity in images from in vivo confocal microscopy. Invest Ophthalmol Vis Sci. 2011;16;52:6404-6408.
22. Rao K, Leveque C, Pflugfelder SC. Corneal nerve regeneration in neurotrophic keratopathy following autologous plasma therapy. Br J Ophthalmol. 2010;94:584-591.
23. Parissi M, Karanis G, Randjelovic S, et al. Standardized baseline human corneal subbasal nerve density for clinical investigations with laser-scanning in vivo confocal microscopy. Invest Ophthalmol Vis Sci. 2013;54:7091-7102.
24. Sacchetti M, Lambiase A, Cortes M, et al. Clinical and cytological findings in limbal stem cell deficiency. Graefes Arch Clin Exp Ophthalmol. 2005;243:870-876.
25. Lambiase A, Rama P, Aloe L, Bonini S. Management of neurotrophic keratopathy. Curr Opin Ophthalmol. 1999;10:270-276.
26. Sacchetti M, Lambiase A, Coassin M, Bonini S, Bonini S. Toxic corneal ulcer: a frequent and sight-threatening disease. Eur J Ophthalmol. 2009;19:916-922.
27. Nishida T, Yanai R. Advances in treatment for neurotrophic keratopathy. Curr Opin Ophthalmol. 2009;20:276-281.
28. Petroutsos G, Guimaraes R, Giraud JP, Pouliquen Y. Corticosteroids and corneal epithelial wound healing. Br J Ophthalmol. 1982;66: 705-708.
29. Hersh PS, Rice BA, Baer JC, et al. Topical nonsteroidal agents and corneal wound healing. Arch Ophthalmol. 1990;108:577-583.
30. Hossain P. The corneal melting point. Eye (Lond). 2012;26: 1029-1030.
31. Perry HD, Golub LM. Systemic tetracyclines in the treatment of noninfected corneal ulcers: a case report and proposed new mechanism of action. Ann Ophthalmol. 1985;17:742-744.
32. Hicks CR, Crawford GJ. Melting after keratoprosthesis implantation: the effects of medroxyprogesterone. Cornea. 2003;22:497-500.
33. Grey F, Carley F, Biswas S, Tromans C. Scleral contact lens management of bilateral exposure and neurotrophic keratopathy. Cont Lens Anterior Eye. 2012;35:288-291.
34. Portnoy SL, Insler MS, Kaufman HE. Surgical management of corneal ulceration and perforation. Surv Ophthalmol. 1989;34:47-58.
35. Khokhar S, Natung T, Sony P, et al. Amniotic membrane transplantation in refractory neurotrophic corneal ulcers: a randomized, controlled clinical trial. Cornea. 2005;24:654-660.
36. Kruse FE, Rohrschneider K, Völcker HE. Multilayer amniotic membrane transplantation for reconstruction of deep corneal ulcers. Ophthalmology. 1999;106:1504-1510.
37. Hurtado-Sarrió M, Duch-Samper A, Cisneros-Lanuza A, Díaz-Llopis M. Tachosil: a new alternative for the treatment of non-traumatic corneal perforations. Br J Ophthalmol. 2009;93:1410-1411.
38. Grau AE, Durán JA. Treatment of a large corneal perforation with a multilayer of amniotic membrane and Tachosil. Cornea. 2012;31:98-100.
39. Gundersen T, Pearlson HR. Conjunctival flaps for corneal diseases: their usefulness and complications. Trans Am Ophthalmol Soc. 1969;67:78-95.
40. Lugo M, Arentsen JJ. Treatment of neurotrophic ulcers with conjunctival flaps. Am J Ophthalmol. 1987;103:711-712.
41. Khodadoust A, Quinter AP. Microsurgical approach to the conjunctival flap. Arch Ophthalmol. 2003;121:1189-1193.
42. Golubović S, Parunović A. [Cyanoacrylate glue in the treatment of corneal ulcerations]. Fortschr Ophthalmol. 1990;87:378-381.German.
43. Hirst LW, Smiddy WE, Stark WJ. Corneal perforations: changing methods of treatment, 1960-1980. Ophthalmology. 1982;89:630-634.
44. Jhanji V, Young AL, Mehta JS, Sharma N, Agarwal T, Vajpayee RB. Management of corneal perforation. Surv Ophthalmol. 2011;56: 522-538.
45. Semeraro F, Forbice E, Romano V, et al. Neurotrophic keratitis. Ophthalmologica. October 2, 2013. [Epub ahead of print.]
46. Terzis JK, Dryer MM, Bodner BI. Corneal neurotization: a novel solution to neurotrophic keratopathy. Plast Reconstr Surg. 2009;123:112-120.
47. Pavan-Langston D, Dohlman CH. Boston keratoprosthesis treatment of herpes zoster neurotrophic keratopathy. Ophthalmology. 2008;115(Suppl 2):S21-S23.
48. Aifa A, Gueudry J, Portmann A, Delcampe A, Muraine M. Topical treatment with a new matrix therapy agent (RGTA) for the treatment of corneal neurotrophic ulcers. Invest Ophthalmol Vis Sci. 2012;53: 8181-8185.
49. Dunn SP, Heidemann DG, Chow CY, et al. Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta4. Ann N Y Acad Sci. 2010;1194:199-206.
50. Jeng BH, Dupps WJ Jr. Autologous serum 50% eye drops in the treatment of persistent corneal epithelial defects. Cornea. 2009;28:1104-1108.
51. Turkoglu E, Celik E, Alagoz G. A comparison of the efficacy of autologous serum eye drops with amniotic membrane transplantation in neurotrophic keratitis. Semin Ophthalmol. June 12, 2013.[Epub ahead of print.]
52. Geremicca W, Fonte C, Vecchio S. Blood components for topical use in tissue regeneration: evaluation of corneal lesions treated with platelet lysate and considerations on repair mechanisms. Blood Transfus. 2010;8:107-112.
53. Yoon KC, You IC, Im SK, Jeong TS, Park YG, Choi J. Application of umbilical cord serum eyedrops for the treatment of neurotrophic keratitis. Ophthalmology. 2007;114:1637-1642.
54. Daniele S, Gilbard JP, Schepens CL. Treatment of persistent epithelial defects in neurotrophic keratitis with epidermal growth factor: a preliminary open study. Graefes Arch Clin Exp Ophthalmol. 1992;230: 314-317.
55. Yamada N, Matsuda R, Morishige N, et al. Open clinical study of eye-drops containing tetrapeptides derived from substance P and insulin-like growth factor-1 for treatment of persistent corneal epithelial defects associated with neurotrophic keratopathy. Br J Ophthalmol. 2008;92:896-900.
56. Nishida T, Chikama T, Morishige N, Yanai R, Yamada N, Saito J. Persistent epithelial defects due to neurotrophic keratopathy treated with a substance P-derived peptide and insulin-like growth factor 1. Jpn J Ophthalmol. 2007;51:442-447.
57. Lambiase A, Rama P, Bonini S, Caprioglio G, Aloe L. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N Engl J Med. 1998;338:1174-1180.
58. Bonini S, Lambiase A, Rama P, Caprioglio G, Aloe L. Topical treatment with nerve growth factor for neurotrophic keratitis. Ophthalmology. 2000;107:1347-1351.
59. Lambiase A, Sacchetti M, Bonini S. Nerve growth factor therapy for corneal disease. Curr Opin Ophthalmol. 2012;23:296-302.
60. Ferrari MP, Mantelli F, Sacchetti M, et al. Safety and pharmacokinetics of escalating doses of human recombinant nerve growth factor eye drops in a double-masked, randomized clinical trial. BioDrugs. December 11, 2013. [Epub ahead of print.]
61. Dompé s.p.a. Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis. (REPARO). Available from: http://clinicaltrials.gov/show/NCT01756456. NLM identifier: NCT01756456. Accessed February 18, 2014.
62. Laboratoires Thea. Efficacy and Safety Assessment of T4020 Versus Vehicule in Patients With Chronic Neurotrophic Keratitis or Corneal Ulcer. Available from: http://clinicaltrials.gov/ct2/show/NCT01794312. NLM identifier: NCT01794312. Accessed February 18, 2014.
63. University of California, San Francisco. Efficacy and Safety Study of Nexagon for Persistent Corneal Epithelial Defects (NTX-PED-001). Available from: http://clinicaltrials.gov/show/NCT01165450. NLM identifier: NCT01165450. Accessed February 18, 2014.